Avista Therapeutics Announces Oral Presentation at Association for Research in Vision and Ophthalmology 2025 Annual Meeting

PITTSBURGH, April 30, 2025 / PR Newswire /— Avista Therapeutics, a pre-clinical-stage biotechnology company developing innovative gene therapies for rare ophthalmic conditions, today announced that the Company will present data highlighting the potential of its scAAVengr-HUnT platform to develop improved AAV capsids at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah taking place May 4-8, 2025.

Oral Presentation Details
Title: Revolutionizing intravitreal gene therapy: Integrating machine learning-guided design of high-complexity AAV capsid libraries with the scAAVengr-HUnT platform
Session Title: i3-guided gene therapy 
Date and Time: Wednesday, May 7 at 2:30-2:45 p.m. MDT
Presentation Number: 4651
Presenter: Laura Campello, Ph.D., Avista Therapeutics

About Avista Therapeutics
Avista Therapeutics’ mission is to develop innovative gene therapies for retinal diseases, including rare ophthalmic conditions that have a profound impact on patients' quality of life. We leverage our computationally guided scAAVengr platform to generate and validate a toolkit of proprietary AAV vectors that target specific cell types using minimally invasive intravitreal delivery with reduced dosages. Our quantitative, in vivo-based approach and clinical ophthalmology expertise allow us to rapidly translate new gene therapies to the clinic.

CONTACTS: 
Investors & Media: 
Argot Partners 
avista@argotpartners.com